Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project

The Multiple Potential Biomarkers for Predicting Immunotherapy Response—Finding the Needle in the Haystack

(2021) Tamiem Adam et al.   Cancers

Harmonization and Standardization of Panel-Based Tumor Mutational Burden (TMB) Measurement: Real-World Results and Recommendations of the QuIP Study

(2020) Albrecht Stenzinger et al.   Journal of Thoracic Oncology

Brief Report: Comparison of three sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer demonstrates low comparability.

(2020) Simon Heeke et al.   Journal of Thoracic Oncology

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project

(2020) Diana M Merino et al.   Journal for ImmunoTherapy of Cancer

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

How current assay approval policies are leading to unintended imprecision medicine

(2020) Roberto Salgado et al.   LANCET ONCOLOGY

Qualification of tumour mutational burden by targeted next‐generation sequencing as a biomarker in hepatocellular carcinoma

(2020) Ching Ngar Wong et al.   LIVER INTERNATIONAL

Tumor mutational burden (TMB) standardization initiatives: Recommendations for consistent TMB assessment in clinical samples to guide immunotherapy treatment decisions

(2019) Albrecht Stenzinger et al.   GENES CHROMOSOMES & CANCER

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

(2019) Zhijie Wang et al.   JAMA Oncology

Optimizing panel-based tumor mutational burden (TMB) measurement

(2019) J Budczies et al.   ANNALS OF ONCOLOGY

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

(2019) Laura Fancello et al.   Journal for ImmunoTherapy of Cancer

Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer

(2019) Ilaria Alborelli et al.   JOURNAL OF PATHOLOGY

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence

(2019) Samuel J. Klempner et al.   ONCOLOGIST

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

(2018) Hira Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?

(2018) Keith M. Kerr   Journal of Thoracic Oncology

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients

(2018) Ari Vanderwalde et al.   Cancer Medicine

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

A machine learning approach for somatic mutation discovery

(2018) Derrick E. Wood et al.   Science Translational Medicine

56PDAnalytic validation of tumor mutational burden as a companion diagnostic for combination immunotherapy in non-small cell lung cancer

(2018) D A Fabrizio et al.   ANNALS OF ONCOLOGY

Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress

(2017) Lina Abdul Karim et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

PD-L1 IHC in NSCLC with a global and methodological perspective

(2017) Erik Thunnissen et al.   LUNG CANCER

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY